Ibalizumab vs Semzuvolimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: CD4 receptor · full HIV pipeline

Ibalizumab · Trogarzo

Marketed by Theratechnologies and partners

Approved in HIVmonoclonal antibody
Weak signal

NCT02707861 · Phase 3 · completed

The study was nonrandomized, open-label, and had no comparator arm, so its results cannot reliably distinguish ibalizumab’s effects from those of the individualized background regimens or other factors. Its primary effectiveness endpoint was a short-term viral-load measure, and the reported results were descriptive rather than a controlled statistical comparison.

Next expected readout: December 2028 · NCT07635992 (registry estimate)

Reported efficacy

Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF (Day 14); Efficacy: Proportion of Subjects With a Viral Load Decrease of at Least 0.5 Log 10 - Protocol Correct (Day 14): Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF (Day 14): Open-Label Ibalizumab Plus OBR 82.5% (95% CI 67.72% to 92.66%) (not_applicable)

Result source: NCT02475629

Semzuvolimab

Developed by United BioPharma

Phase 3 in HIVmonoclonal antibody
Weak signal

NCT04404049 · Phase 2 · status unknown

This is a small, open-label randomized study comparing two dosing schedules of add-on Semzuvolimab against standard therapy alone in people already on antiretroviral therapy. The primary measure is treatment-related side effects rather than a virologic or clinical outcome, and results are not yet available, so the evidence for Semzuvolimab's clinical benefit cannot yet be assessed. Its registered primary outcome on ClinicalTrials.gov is "treatment related TEAEs". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT04985890 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIbalizumabSemzuvolimab
HIV-1 RNA below 50 copies/mL (week 48)—Not reported—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Not reported—Not reported
CD4 count, change (week 48)—Not reported—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Ibalizumab
—Not reported
Semzuvolimab
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Ibalizumab
—Not reported
Semzuvolimab
—Not reported

CD4 count, change (week 48)

Ibalizumab
—Not reported
Semzuvolimab
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Semzuvolimab: no structured comparison results are available for HIV.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ibalizumab: 4 of 4 rows · Semzuvolimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIbalizumab
Dropout rate
n/a: no completion milestoneCohort 1a
NCT02707861 · Phase 3 · combination · HIV · phase 3
show 4 more results
n/a: no completion milestoneCohort 2
NCT02707861 · Phase 3 · combination · HIV · phase 3
22.5%
NCT02475629 · Phase 3 · combination · HIV · phase 3
13.6%800 mg
NCT00784147 · Phase 2 · registry result, not featured evidence
16.7%2000 mg
NCT00784147 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
4.9%Cohort 1a
NCT02707861 · Phase 3 · combination · HIV · phase 3
show 4 more results
7.9%Cohort 2
NCT02707861 · Phase 3 · combination · HIV · phase 3
2.5%
NCT02475629 · Phase 3 · combination · HIV · phase 3
—800 mg
NCT00784147 · Phase 2 · registry result, not featured evidence
—2000 mg
NCT00784147 · Phase 2 · registry result, not featured evidence
Serious AEs
39%Cohort 1a
NCT02707861 · Phase 3 · combination · HIV · phase 3
show 4 more results
39.5%Cohort 2
NCT02707861 · Phase 3 · combination · HIV · phase 3
22.5%
NCT02475629 · Phase 3 · combination · HIV · phase 3
11.9%800 mg
NCT00784147 · Phase 2 · registry result, not featured evidence
5.6%2000 mg
NCT00784147 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
diarrhea 41.5%
rash 41.5%
headache 19.5%
NCT02707861 · Phase 3 · combination · HIV · phase 3
show 4 more results
diarrhea 26.3%
headache 26.3%
nausea 23.7%
NCT02707861 · Phase 3 · combination · HIV · phase 3
diarrhoea 20%
dizziness 12.5%
fatigue 12.5%
NCT02475629 · Phase 3 · combination · HIV · phase 3
800 mg
cough 10.2%
rash 8.5%
dizziness 6.8%
NCT00784147 · Phase 2 · registry result, not featured evidence
2000 mg
rash 16.7%
nausea 13%
diarrhea 11.1%
NCT00784147 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ibalizumab

HIV-1 RNA 0 5 log10 Decrease 73.7% (n=38) @ 1wk
event count · % of participants
No placebo or comparator arm
NCT02707861 · Phase 3 · combination · HIV · phase 3 · converted to % from 28 participants as posted
HIV-1 RNA Less Than 50 Copies 64.7% (n=17) @ 48wk
event count · % of participants
No placebo or comparator arm
NCT02707861 · Phase 3 · combination · HIV · phase 3 · converted to % from 11 Participants as posted
HIV-1 RNA Less Than 400 Copies 58.8% (n=17) @ 48wk
event count · % of participants
No placebo or comparator arm
NCT02707861 · Phase 3 · combination · HIV · phase 3 · converted to % from 10 Participants as posted
HIV-1 RNA 1 log10 Decrease 0 @ 48wk
event count · % of participants
No placebo or comparator arm
NCT02707861 · Phase 3 · combination · HIV · phase 3 · converted to % from 0 Participants as posted
show 1 more result
64.7% (n=17) @ 48wk*
NCT02707861 · Phase 3 · combination · HIV · phase 3 · converted to % from 11 Participants as posted
HIV RNA 0.5 Log 10 Reduction 0.825% (n=40) @ 2wk
event count · % of participants
No placebo or comparator arm
NCT02475629 · Phase 3 · combination · HIV · phase 3
show 1 more result
0.846% (n=26) @ 2wk
NCT02475629 · Phase 3 · combination · HIV · phase 3
HIV-1 RNA -1.6 log @ 24wk800 mg
absolute change · log
No placebo or comparator arm
NCT00784147 · Phase 2 · registry result, not featured evidence
show 3 more results
-1.5 log @ 24wk2000 mg
NCT00784147 · Phase 2 · registry result, not featured evidence
-1.07 log
NCT02475629 · Phase 3 · combination · HIV · phase 3
-1.11 log
NCT02475629 · Phase 3 · combination · HIV · phase 3
HIV RNA 0.5 Log 10 Reduction 0.625% (n=40) @ 25wk
event count · % of participants
No placebo or comparator arm
>/= 0.5 log10 reduction
NCT02475629 · Phase 3 · combination · HIV · phase 3
show 1 more result
0.962% (n=26) @ 25wk
>/= 0.5 log10 reduction
NCT02475629 · Phase 3 · combination · HIV · phase 3
HIV-1 RNA 1 log10 Decrease 0.55% (n=40) @ 25wk
event count · % of participants
No placebo or comparator arm
>/= 1.0 log10 reduction
NCT02475629 · Phase 3 · combination · HIV · phase 3
show 1 more result
0.846% (n=26) @ 25wk
>/= 1.0 log10 reduction
NCT02475629 · Phase 3 · combination · HIV · phase 3
CD4+ 36.5 cells/uL @ 24wk800 mg
absolute change · cells/uL
No placebo or comparator arm
NCT00784147 · Phase 2 · registry result, not featured evidence
show 3 more results
39.8 cells/uL @ 24wk2000 mg
NCT00784147 · Phase 2 · registry result, not featured evidence
62.4 cells/uL
NCT02475629 · Phase 3 · combination · HIV · phase 3
67 cells/uL
NCT02475629 · Phase 3 · combination · HIV · phase 3
HIV-1 RNA Lt50 Copies 44% (n=59) @ 24wk800 mg
responder rate · % of participants
No placebo or comparator arm
NCT00784147 · Phase 2 · registry result, not featured evidence
show 1 more result
28% (n=54) @ 24wk2000 mg
NCT00784147 · Phase 2 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies 53% (n=59) @ 24wk800 mg
absolute value · percentage points
No placebo or comparator arm
NCT00784147 · Phase 2 · registry result, not featured evidence
show 1 more result
43% (n=54) @ 24wk2000 mg
NCT00784147 · Phase 2 · registry result, not featured evidence
HIV-1 RNA LT 400 Copies 58% (n=59) @ 24wk800 mg
absolute value · percentage points
No placebo or comparator arm
NCT00784147 · Phase 2 · registry result, not featured evidence
show 1 more result
46% (n=54) @ 24wk2000 mg
NCT00784147 · Phase 2 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ibalizumab's landscape · Semzuvolimab's landscape